FLT3 and acute myeloid leukemia: In addition, we propose that gilteritinib may be a good combination drug with chemotherapies that increase plasma concentrations of FL in FLT3-mutated AML patients and/or an effective monotherapy for AML patients with FL upregulation after chemotherapy.